NASDAQ:NVCT

Nuvectis Pharma (NVCT) Stock Forecast, Price & News

$17.47

-0.11 (-0.63%)

(As of 12:55 PM ET)

Compare

Today's Range: $16.86
▼
$17.57
50-Day Range: $11.75
▼
$17.60
52-Week Range: $6.21
▼
$17.82

Volume: 34,511 shs
Average Volume: 50,430 shs
Market Capitalization: $279.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Nuvectis Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 21.0% Upside
$21.00 Price Target
Short Interest: Bearish
6.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.28
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$59,450 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.19) to ($1.27) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

Medical Sector

875th out of 980 stocks

Pharmaceutical Preparations Industry

438th out of 485 stocks

2.5

Analyst's Opinion

Consensus Rating
Nuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, Nuvectis Pharma has a forecasted upside of 21.0% from its current price of $17.36.
Amount of Analyst Coverage
Nuvectis Pharma has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.99% of the float of Nuvectis Pharma has been sold short.
Short Interest Ratio / Days to Cover
Nuvectis Pharma has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in Nuvectis Pharma has recently increased by 34.72%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nuvectis Pharma does not currently pay a dividend.
Dividend Growth
Nuvectis Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NVCT.

2.9

News and Social Media Coverage

News Sentiment
Nuvectis Pharma has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Nuvectis Pharma this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NVCT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $59,450.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
38.85% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.68% of the stock of Nuvectis Pharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nuvectis Pharma are expected to decrease in the coming year, from ($1.19) to ($1.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nuvectis Pharma is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nuvectis Pharma is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nuvectis Pharma has a P/B Ratio of 17.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nuvectis Pharma (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

NVCT Stock News Headlines

May 31, 2023 | finance.yahoo.com

3 Best Breakout Stocks Worth Buying for Superlative Returns

May 19, 2023 | finance.yahoo.com

Here's What Could Help Nuvectis Pharma, Inc. (NVCT) Maintain Its Recent Price Strength

June 5, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.

May 16, 2023 | americanbankingnews.com

HC Wainwright Equities Analysts Increase Earnings Estimates for Nuvectis Pharma, Inc. (NASDAQ:NVCT)

May 15, 2023 | finance.yahoo.com

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023 | finance.yahoo.com

Wall Street Analysts Think Nuvectis Pharma, Inc. (NVCT) Could Surge 29.35%: Read This Before Placing a Bet

May 11, 2023 | msn.com

Nuvectis Pharma: Q1 Earnings Insights

May 10, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Nuvectis Pharma (NVCT)

June 5, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

May 10, 2023 | finance.yahoo.com

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023 | finance.yahoo.com

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

April 19, 2023 | americanbankingnews.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest Up 23.2% in March

April 18, 2023 | finance.yahoo.com

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting

April 10, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Nuvectis Pharma (NVCT)

April 6, 2023 | americanbankingnews.com

Reviewing Nuvectis Pharma (NVCT) and Its Rivals

April 5, 2023 | finance.yahoo.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have recently purchased stock and their bets paid off last week as company hit US$198m market cap

March 29, 2023 | americanbankingnews.com

Head to Head Survey: Nuvectis Pharma (NVCT) versus Its Rivals

March 17, 2023 | finance.yahoo.com

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

March 10, 2023 | finance.yahoo.com

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

March 9, 2023 | finance.yahoo.com

Bullish insiders bet US$1.1m on Nuvectis Pharma, Inc. (NASDAQ:NVCT)

March 3, 2023 | uk.finance.yahoo.com

Nuvectis Pharma, Inc. (NVCT)

February 23, 2023 | finance.yahoo.com

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

February 16, 2023 | seekingalpha.com

NVCT Nuvectis Pharma, Inc.

February 9, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

February 9, 2023 | finance.yahoo.com

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®

January 4, 2023 | finance.yahoo.com

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

December 31, 2022 | finance.yahoo.com

Is Nuvectis Pharma, Inc. (NASDAQ:NVCT) Trading At A 33% Discount?

See More Headlines

NVCT Price History

30 days | 90 days | 365 days | Advanced Chart

NVCT Company Calendar

Last Earnings: 3/07/2023
Today: 6/05/2023
Next Earnings (Estimated): 8/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NVCT
CUSIP: N/A
CIK: 1875558
Web: www.nuvectis.com
Phone: 201-614-3150
Fax: N/A
Employees: 8
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.00
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $21.00
Forecasted Upside/Downside: +19.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -138.37%
Return on Assets: -106.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.12
Quick Ratio: 4.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.77 per share
Price / Book: 22.83

Miscellaneous

Outstanding Shares: 16,010,000
Free Float: 9,591,000
Market Cap: $281.46 million
Optionable: Not Optionable
Beta: 0.37

Key Executives

Mr. Ron Bentsur M.B.A. (Age 56)
Co-Founder, Chairman, CEO & Pres

Dr. Enrique Poradosu Ph.D. (Age 55)
Co-Founder, Exec. VP, Chief Scientific & Bus. Officer
Comp: $27.08k

Mr. Shay Shemesh (Age 38)
Co-Founder, EVP, Chief Devel. & Operations Officer
Comp: $27.08k

Mr. Michael Carson CPA (Age 46)
VP of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVCT Stock - Frequently Asked Questions

Should I buy or sell Nuvectis Pharma stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NVCT shares.
View NVCT analyst ratings or view top-rated stocks.
What is Nuvectis Pharma's stock price forecast for 2023?: 2 brokers have issued 1 year target prices for Nuvectis Pharma's shares. Their NVCT share price forecasts range from $21.00 to $21.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for NVCT or view top-rated stocks among Wall Street analysts.
How have NVCT shares performed in 2023?: Nuvectis Pharma's stock was trading at $7.50 at the start of the year. Since then, NVCT stock has increased by 134.4% and is now trading at $17.58.
View the best growth stocks for 2023 here.
Are investors shorting Nuvectis Pharma?: Nuvectis Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 297,600 shares, an increase of 34.7% from the April 30th total of 220,900 shares. Based on an average daily volume of 27,100 shares, the short-interest ratio is currently 11.0 days. Currently, 7.0% of the company's shares are short sold.
View Nuvectis Pharma's Short Interest.
When is Nuvectis Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our NVCT earnings forecast.
How were Nuvectis Pharma's earnings last quarter?: Nuvectis Pharma, Inc. (NASDAQ:NVCT) announced its quarterly earnings results on Tuesday, March, 7th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.12.

When did Nuvectis Pharma IPO?: (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share.
What is Nuvectis Pharma's stock symbol?: Nuvectis Pharma trades on the NASDAQ under the ticker symbol "NVCT."
Who are Nuvectis Pharma's major shareholders?: Nuvectis Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baldwin Brothers LLC MA (0.97%), Geode Capital Management LLC (0.24%), Edmond DE Rothschild Holding S.A. (0.17%), BlackRock Inc. (0.09%), State Street Corp (0.09%) and Jane Street Group LLC (0.08%). Insiders that own company stock include Enrique Poradosu, Kenneth Hoberman, Ron Bentsur and Shay Shemesh.
View institutional ownership trends.
How do I buy shares of Nuvectis Pharma?: Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nuvectis Pharma's stock price today?: One share of NVCT stock can currently be purchased for approximately $17.58.
How much money does Nuvectis Pharma make?: Nuvectis Pharma (NASDAQ:NVCT) has a market capitalization of $281.46 million. The company earns $-19,080,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.
How can I contact Nuvectis Pharma?: The official website for the company is www.nuvectis.com. The company can be reached via phone at 201-614-3150.

This page (NASDAQ:NVCT) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial